أستراليا -
الإنجليزية -
Department of Health (Therapeutic Goods Administration)
astrzeneca goserelin goserelin 10.8mg (as acetate) implant syringe
astrazeneca pty ltd - goserelin, quantity: 10.8 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer , where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation.
أيرلندا -
الإنجليزية -
HPRA (Health Products Regulatory Authority)
zoladex
astrazeneca uk limited - goserelin acetate - implant - 3.6 base milligrams - goserelin
أيرلندا -
الإنجليزية -
HPRA (Health Products Regulatory Authority)
zoladex la
astrazeneca uk limited - goserelin acetate - implant - 10.8 base milligrams - goserelin
مالطا -
الإنجليزية -
Malta Medicines Authority
zoladex 3.6mg implant
astrazeneca uk limited - goserelin - implant - goserelin - endocrine therapy
مالطا -
الإنجليزية -
Malta Medicines Authority
zoladex la 10.8mg implant
astrazeneca uk limited - goserelin - implant - goserelin - endocrine therapy
نيوزيلاندا -
الإنجليزية -
Medsafe (Medicines Safety Authority)
esmya
pharmacy retailing (nz) ltd t/a healthcare logistics - ulipristal acetate 5mg - tablet - 5 mg - active: ulipristal acetate 5mg excipient: croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose purified talc - ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
أستراليا -
الإنجليزية -
Department of Health (Therapeutic Goods Administration)
eligard leuprorelin acetate 30mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.
أستراليا -
الإنجليزية -
Department of Health (Therapeutic Goods Administration)
eligard leuprorelin acetate 22.5mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.
أستراليا -
الإنجليزية -
Department of Health (Therapeutic Goods Administration)
eligard leuprorelin acetate 7.5mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1
مالطا -
الإنجليزية -
Malta Medicines Authority
zoladex 3.6mg implant
astrazeneca ab se-151 85, södertälje, sweden - goserelin - implant - goserelin 3.6 mg - endocrine therapy